Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1FS0F)

• Drug Name: VH4524184 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM1FS0F

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Integrase (HIV IN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolutegravir	DMCZGRE	Human immunodeficiency virus infection	1C62	Approved	[3]
Raltegravir	DMYURI6	Human immunodeficiency virus infection	1C62	Approved	[4]
Elvitegravir	DMG9B1U	Human immunodeficiency virus infection	1C62	Approved	[3]
Bictegravir, emtricitabine and tenofovir alafenamide	DMG0H8K	Human immunodeficiency virus infection	1C62	Approved	[5]
GSK1265744	DMT8J0I	Human immunodeficiency virus infection	1C62	Phase 3	[6]
S-1360	DM9KTSG	Human immunodeficiency virus infection	1C62	Phase 2	[7]
S-364735	DMU7ZMH	Human immunodeficiency virus infection	1C62	Phase 2	[8]
C-2507	DMOFT1V	Human immunodeficiency virus infection	1C62	Phase 1	[9]
Acriflavine	DMKVE8X	Human immunodeficiency virus infection	1C62	Phase 1	[10]
S-265744 LAP	DMDQRWT	Human immunodeficiency virus infection	1C62	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Integrase (HIV IN)	TT5FH9Y	POL_HV1B1	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT05631704) A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single and Multiple Ascending Dose First-Time-in-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of ViiV Healthcare
• [3] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [4] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68.
• [8] The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8.
• [9] Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85.
• [10] Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6.
• [11] Long-acting shot prevents infection with HIV analogue. Nature. doi:10.1038/nature.2014.14819. 04 March 2014